CHEK1 and neuroblastoma: Using RNAi loss-of-function screens, CHK1 was identified as a potent target in NB and further preclinical validation studies have demonstrated exceptional in vitro and in vivo efficacy of the CHK1 inhibitor, prexasertib (31–33).